Clinical trials: HIV Viremia
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
HIV Infections
A Study to Monitor Patients With Primary or Early HIV Infection
The purpose of this study is to monitor patients who recently have been infected with HIV in order to learn how their immune systems respond to HIV infection and to study how the virus acts in their bodies.
- Trial name
- NCT00000911
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels.
- Trial name
- NCT00414284
- Testing
- Increased dose of Kaletra
- Where
- United States
- Sponsor
- Community Research Initiative of New England
HIV-1 Infection
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
Viral eradication in selected HIV-infected patients is possible with intensive antiretroviral therapy plus immunomodulation
- Trial name
- ERAMUNE-01 (NCT01019551)
- Testing
- ART Intensification, Immunomodulation
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 29 people
- Sponsor
- Objectif Recherche Vaccins SIDA
HIV-1-infection, ART
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving…
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection
- Trial name
- NCT05700630
- Testing
- FT538, Vorinostat
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
HIV Infections
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in vitro activity against HIV-1 strains including those resistant to currently available antiretroviral drugs.
- Trial name
- NCT00515827
- Testing
- Raltegravir (MK-0518)
- Where
- 20 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy.
- Trial name
- NCT00114933
- Testing
- Stopping nucleosides and continuing lopinavir/ritonavir monotherapy
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Arribas, Jose R., M.D.
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
HIV Infection
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia
The medicines used to treat HIV can suppress but cannot kill all the virus in the body. A small amount of virus remains at low levels in the part of the blood called the plasma.
- Trial name
- NCT00618371
- Testing
- Raltegravir (MK-0518)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
HIV Infections
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
Drug resistance may develop in HIV infected patients who take anti-HIV drugs, but most patients do well if they continue taking them.
- Trial name
- NCT00102934
- Testing
- Enfuvirtide-intensified HAART
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
- Trial name
- NCT00051038
- Testing
- Entecavir
- Where
- 5 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
The objective of antiretroviral therapy (ART) is the maintenance of HIV viral suppression, the optimal condition to prevent disease progression, to optimize immune restoration, to prevent the development of viral resistance and…
- Trial name
- DORAL (NCT04513626)
- Testing
- DORAVIRINE 100 MG [Pifeltro]
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Viremia
Optimizing a Bio-behavioral Intervention for Sustained Viral Suppression
The study will test two behavioral intervention components to identify the combination of the two components that best supports people who inject drugs to achieve and sustain HIV viral load suppression.
- Trial name
- NCT05377463
- Testing
- Peer support to promote uptake and persistence of medication assisted treatment (MAT), Behavioral Activation Treatment (BAT) to reduce depression, No Intervention Components
- Where
- Mexico
- Volunteers
- 220 people
- Sponsor
- University of Texas, El Paso
Human Immunodeficiency Virus I Infection
Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses
The FXReservoir#1 study (NCT03618862) showed that certain FXR ligands reactivate latent viruses in the reservoir circulating in all HIV+ patients tested.
- Trial name
- FXR#2 (NCT05219916)
- Testing
- Blood collection.
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Hospices Civils de Lyon
HIV
Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy
Low-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent event, generating stress for both patient and physician, due to the fear of subsequent virological escape with emergence of…
- Trial name
- ViPer (NCT07015164)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections, Stomatitis, Aphthous
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection
PRIMARY: To evaluate the effectiveness and safety of thalidomide for treatment of oral and esophageal aphthous ulcers (those unrelated to a known infection or malignancy) in patients with advanced HIV disease.
- Trial name
- NCT00000790
- Testing
- Thalidomide
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Alternative Dosing Strategy for Anti-HIV Drugs
Anti-HIV drugs are usually given to patients at fixed, standardized doses. This study will investigate alternative ways of dosing anti-HIV drugs to improve viral control.
- Trial name
- NCT00059384
- Testing
- Concentration-controlled therapy
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Transmission Vertical
Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their Infants
Differentiated service delivery (DSD) is an evidence-based HIV care and treatment model endorsed by the World Health Organization (WHO) that simplifies HIV services for clients who are clinically stable, improving the quality and…
- Conditions
- Hiv, Transmission Vertical, Viremia, Health Care Acceptability
- Trial name
- NCT06629753
- Testing
- Differentiated service delivery model
- Where
- Kenya
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Indiana University
Cytomegalovirus Infections, HIV Infections
Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV
Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is…
- Trial name
- NCT00006145
- Testing
- Valganciclovir
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 350 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Alcohol Drinking, HIV Viremia
Using Telehealth to Address Alcohol Misuse in HIV Care
This project will test the effects of a telehealth counseling program on reducing alcohol use and improving HIV viral control among people with HIV who drink heavily.
- Trial name
- ReACH3 (NCT04546971)
- Testing
- Brief Intervention, Telehealth Counseling, Text messaging
- Where
- United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Brown University